Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission

Basit Öğe Kaydı
dc.contributor.authorErdogan, Mehmet
dc.contributor.authorOzbek, Mustafa
dc.contributor.authorAkbal, Erdem
dc.contributor.authorUreten, Kemal
dc.date.accessioned2025-01-27T20:29:35Z
dc.date.available2025-01-27T20:29:35Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground/aim: Acromegaly is associated with increased morbidity and mortality, mostly due to cardiovascular complications. Plasma thrombin-activatablc fibrinolysis inhibitor (TAFI) antigen levels arc associated with coagulation/fibrinolysis and inflammation. Plasma TAFI may play a role in arterial thrombosis in cardiovascular diseases. In this study, it was aimed to evaluate the thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and homocysteine levels in patients with acromegaly and healthy control subjects. Materials and methods: Plasma TAFI antigen and homocysteine levels in 29 consecutive patients with acromegaly and 26 age-matched healthy control subjects were measured. All patients included in the study were in remission. The TAFIa/ai antigen in the plasma samples was measured using a commercially available ELISA kit. Results: Routine biochemical parameters, fasting blood glucose, prolactin, thyroid stimulating hormone, total-cholesterol, low density lipoprotein cholesterol, triglyceride, and homocysteine levels were similar in the 2 groups (P > 0.05), whereas the plasma TAFI antigen levels were significantly elevated in the acromegalic patients (154.7 +/- 94.0%) when compared with the control subjects (107.2 +/- 61.6%) (P = 0.033). No significant correlation was identified by Pearson's correlation test between the plasma TAFI antigen and homocysteine levels (r = 0.320, P = 0.250). Conclusion: A significant alteration in the plasma TAFI antigen levels was detected in acromegaly. Increased plasma TAFI antigen levels might aggravate prothrombotic and thrombotic events in patients with acromegaly.
dc.identifier.doi10.3906/sag-1812-231
dc.identifier.endpage1385
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5
dc.identifier.pmid31549496
dc.identifier.scopus2-s2.0-85074117903
dc.identifier.scopusqualityQ1
dc.identifier.startpage1381
dc.identifier.trdizinid336720
dc.identifier.urihttps://doi.org/10.3906/sag-1812-231
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/336720
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22988
dc.identifier.volume49
dc.identifier.wosWOS:000504050500017
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectTAFI antigen
dc.subjectacromegaly
dc.subjectcardiovascular disease
dc.titlePlasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu